Blocking Myc to Treat Cancer: Reflecting on Two Decades of Omomyc

Area of Science:

• Oncology
• Molecular Biology
• Drug Development

Background:

• Omomyc was initially developed in 1998 as a laboratory tool to investigate Myc perturbation.
• Over 22 years, Omomyc has been instrumental in understanding Myc biology in various cellular and animal models.
• It has exhibited notable anti-cancer effects across diverse tumor types.

Purpose of the Study:

• To highlight the evolution of Omomyc from a research tool to a potential therapeutic agent.
• To underscore the significance of Omomyc's cell-penetrating capacity.
• To report the progression of Omomyc into clinical drug development for cancer therapy.

Main Methods:

• Expression of Omomyc in normal and cancer cells.
• Utilisation of genetically-engineered mouse models.
• Administration of purified Omomyc mini-protein, leveraging its cell-penetrating properties.

Main Results:

• Omomyc has significantly contributed to the understanding of Myc biology.
• Demonstrated remarkable anti-cancer properties in a wide range of tumor types.
• The purified Omomyc mini-protein shows therapeutic potential due to its cell-penetrating capacity.

Conclusions:

• Omomyc's journey from a lab tool to a therapeutic candidate represents a paradigm shift in Myc inhibition.
• The discovery of its cell-penetrating ability is key to its therapeutic application.
• Omomyc is advancing in the drug development pipeline, bringing Myc inhibition closer to clinical application.